BTAI - バイオエクセル・セラピュ―ティクス （BioXcel Therapeutics Inc.）

NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2022 financial results on Thursday, November 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company’s financial results and to provide a general business update.

BioXcel Therapeutics Inc. (BTAI)’s stock has witnessed a price hike of 6.76% from the previous close with its current price standing at $11.05. Its current price is -69.72% under its 52-week high of $36.49 and 25.64% more than its 52-week low of $8.80. Based on the past 30-day period, the stock price is -15.82% below […]

NEW HAVEN, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Commercial Day presentation for the investment community to provide an update on its recently launched product, IGALMI (dexmedetomidine)

The following slide deck was published by BioXcel Therapeutics, Inc.

NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and

BioXcel Therapeutics Inc (BTAI) shares closed today 12.3% higher than it did at the end of yesterday. The stock is currently up 12.3% year-to-date, down 50.6% over the past 12 months, and up 107.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $22.94 and as low as $19.66 this week.Shares closed 66.3% below its 52-week high and 22.0% above its 52-week low.Trading volume this week was 59.0% higher than the 10-day average and 56.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance over the past 12 months lags the peer average by 62.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Two Phase 3 studies to enroll a total of 300 patients in assisted living or residential facilities and nursing homes to evaluate the safety and efficacy of BXCL501

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update FDA Review of BXCL501 Extended to April 5, 2022 On December 1, 2021, BioXcel Therapeutics, Inc. (NASDAQ:

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update PDUFA Data of Jan. 5, 2022 for BXCL501; MAA Filing Expected in 1H22 In May 2021, BioXcel Therapeutics, Inc. (NASDAQ:

In last trading session, BioXcel Therapeutics Inc. (NASDAQ:BTAI) saw 1.0 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $20.43 trading at -$2.5 or -10.90% at ring of the bell on the day assigns it a market valuation of $561.62M. That closing price of BTAI’s stock is … BioXcel Therapeutics Inc. (NASDAQ:BTAI) Decline -10.90%, More Rally Possible Read More »

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update FDA Review of BXCL501 Extended to April 5, 2022 On December 1, 2021, BioXcel Therapeutics, Inc. (NASDAQ:

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update PDUFA Data of Jan. 5, 2022 for BXCL501; MAA Filing Expected in 1H22 In May 2021, BioXcel Therapeutics, Inc. (NASDAQ:

In last trading session, BioXcel Therapeutics Inc. (NASDAQ:BTAI) saw 1.0 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $20.43 trading at -$2.5 or -10.90% at ring of the bell on the day assigns it a market valuation of $561.62M. That closing price of BTAI’s stock is … BioXcel Therapeutics Inc. (NASDAQ:BTAI) Decline -10.90%, More Rally Possible Read More »

BioXcel Therapeutics, Inc. (NASDAQ:BTAI)s share price gapped down prior to trading on Wednesday . The stock had previously closed at $22.93, but opened at $17.31. BioXcel Therapeutics shares last traded at $19.91, with a volume of 3,915 shares trading hands. Several equities analysts have commented on the company. Berenberg Bank reiterated a buy rating and []